Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kymera Therapeutics, Inc. (KYMR) vs TG Therapeutics, Inc. (TGTX)

Kymera Therapeutics, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Kymera Therapeutics, Inc. is the larger, with a market value of $9.7B against $8.8B — 1.1× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 18.9×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 76.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −285.3%) and the higher return on invested capital (10.7% vs −26.7%). Across the 18 metrics below, TG Therapeutics, Inc. leads on 13 and Kymera Therapeutics, Inc. on 5.

Valuation

Metric KYMR TGTX Biotechnology median
P/E n/m 18.89 7.88
P/S 105.17 10.18 11.47
P/B 7.32 13.48 2.52
Price to free cash flow n/m 468.33 21.16
EV/EBITDA n/m 61.31 0.74
EV/Sales 98.60 10.43 10.73
Earnings yield (2.88%) 5.29% (28.84%)
Free cash flow yield (2.15%) 0.21% (23.03%)

Profitability

Metric KYMR TGTX Biotechnology median
Gross margin 100.00% 82.37% 65.16%
Operating margin (333.50%) 17.05% 0.00%
Net margin (285.33%) 55.22% 0.00%
Free cash flow margin (226.62%) 2.17% 0.00%
Return on equity (24.15%) 100.28% (57.72%)
Return on assets (21.58%) 37.70% (49.22%)
Return on invested capital (26.72%) 10.69% 0.00%

Growth

Metric KYMR TGTX Biotechnology median
Revenue growth (TTM) 134.84% 76.08% 5.64%
EPS growth (last fiscal year) (23.83%) 1,746.67% —
Revenue growth, 5-year CAGR 2.87% 426.73% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KYMR TGTX Biotechnology median
Debt to equity 0.00 1.23 0.00
Current ratio 10.34 4.27 4.73
Net debt to EBITDA 2.42 0.86 0.96

Dividend

Metric KYMR TGTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KYMR TGTX Biotechnology median
Market cap 9.69b 8.80b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack